AOP Orphan, Shield Therapeutics sales and marketing update

Shield Therapeutics’ Shield Holdings AG granted AOP Orphan commercialization rights to ST10-021 in Central Eastern Europe and the Middle East. Shield will receive an upfront payment of €1.3 million ($...